Systemic Treatment for Patients with HER2-Positive Breast Cancer and Brain Metastases

Wing-Lok Chan^*

Department of Clinical Oncology, LKS, The University of Hong Kong, Hong Kong

*Corresponding Author : Wing-Lok Chan
Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, 1/F Professorial Block, Queen Mary Hospital, Hong Kong
Tel: 852-22553111
E-mail: winglok@hku.hk

Received: September 03, 2021 Accepted: December 11, 2021 Published: December 25, 2021

Citation: Chan WL (2021) Systemic Treatment for Patients with HER2-Positive Breast Cancer and Brain Metastases. Clin Oncol Case Rep 4:12.

There is no consensus on the treatment of brain metastases in patients with HER2-positive breast cancer. This article reported a patient attained long intracranial control and survival with the use of multiple anti-HER2 agents. Treatment of brain metastases in patients with HER2-positive breast cancer should involve both local therapies and systemic anti-HER2 agents. Radiotherapy and surgery can disrupt the blood-brain barrier. This, in turn, allows the larger molecules like trastuzumab and pertuzumab to penetrate through for better control in the brain metastases. Novel anti-HER2 agents including lapatinib, neratinib, trastuzumab emtansine (TDM1), trastuzumab deruxtecan (T-DXd) can penetrate the bloodbrain barrier and can attain significant improvement in the response of the brain metastases.